In ovarian cancer, calcium/calmodulin-dependent protein kinase II gamma (CAMK2G) facilitates adaptive redox homeostasis upon cisplatin treatment and drives cisplatin resistance by controlling the phosphorylation of ITPKB at serine 174 [11]. Here, CAMK2G is linked to ovarian cancer.